These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34935528)

  • 21. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
    Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
    Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
    Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
    Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
    Zhang Z; Yan S; Cui H; Chen H; Liu J
    Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between
    Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
    Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
    Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
    Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
    Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
    Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypermethylation of genes on chromosome 3p as a biomarker for nasopharyngeal carcinoma diagnosis: A Vietnamese case-control study.
    Lao TD; Le TAH
    Int J Biol Markers; 2024 Sep; 39(3):201-208. PubMed ID: 39149888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification.
    Ooft ML; van Ipenburg J; van Loo R; de Jong R; Moelans C; Braunius W; de Bree R; van Diest P; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
    J Clin Pathol; 2018 Apr; 71(4):351-359. PubMed ID: 28893862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
    Wen G; Wang H; Zhong Z
    Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
    Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
    Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
    Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
    Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
    Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
    Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.
    Ge YZ; Xu LW; Jia RP; Xu Z; Feng YM; Wu R; Yu P; Zhao Y; Gui ZL; Tan SJ; Song Q
    Tumour Biol; 2014 Apr; 35(4):3881-90. PubMed ID: 24353088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
    Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
    PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
    Li YS; Xie Q; Yang DY; Zheng Y
    Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting.
    Yang X; Dai W; Kwong DL; Szeto CY; Wong EH; Ng WT; Lee AW; Ngan RK; Yau CC; Tung SY; Lung ML
    Int J Cancer; 2015 Feb; 136(4):E127-35. PubMed ID: 25196065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
    Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.